EGFR and neoplasm: Next‐generation sequencing (NGS) of tumor tissue showed an EGFR 19del mutation (mutant allele frequency [MAF], 47.2%), MET amplification (copy number 2.1), and TP53 (MAF, 36.5%) mutation.